Novavax (NVAX) Gross Margin (2021 - 2025)
Historic Gross Margin for Novavax (NVAX) over the last 11 years, with Q3 2025 value amounting to 69.49%.
- Novavax's Gross Margin rose 412100.0% to 69.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.24%, marking a year-over-year increase of 275100.0%. This contributed to the annual value of 70.28% for FY2024, which is 52300.0% up from last year.
- According to the latest figures from Q3 2025, Novavax's Gross Margin is 69.49%, which was up 412100.0% from 91.24% recorded in Q2 2025.
- In the past 5 years, Novavax's Gross Margin ranged from a high of 100.0% in Q1 2021 and a low of 45.8% during Q2 2022
- In the last 5 years, Novavax's Gross Margin had a median value of 69.49% in 2025 and averaged 65.89%.
- In the last 5 years, Novavax's Gross Margin crashed by -1458000bps in 2022 and then soared by 1326600bps in 2023.
- Quarter analysis of 5 years shows Novavax's Gross Margin stood at 100.0% in 2021, then crashed by -51bps to 49.14% in 2022, then fell by -5bps to 46.81% in 2023, then increased by 25bps to 58.48% in 2024, then grew by 19bps to 69.49% in 2025.
- Its Gross Margin stands at 69.49% for Q3 2025, versus 91.24% for Q2 2025 and 97.88% for Q1 2025.